Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADaptiVe Biomarker Trial That InformS Evolution of Therapy

Trial Profile

ADaptiVe Biomarker Trial That InformS Evolution of Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs BMS 986156 (Primary) ; Cabiralizumab (Primary) ; Ipilimumab (Primary) ; Linrodostat (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms ADVISE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Dec 2018 Planned End Date changed from 31 Jan 2022 to 16 Apr 2022.
    • 19 Dec 2018 Planned primary completion date changed from 30 Jan 2020 to 15 Apr 2020.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top